What CAR-T therapy is
CAR-T is a form of immunotherapy in which the patient’s T cells, part of the immune system, are collected from the blood, genetically modified in a laboratory and then given back. After modification, the cells carry a new receptor (CAR – chimeric antigen receptor) that lets them recognise a target on cancer cells, for example the CD19 or BCMA protein.
How treatment works
- Cell collection through a procedure called apheresis, similar to a longer blood donation.
- Manufacturing the CAR-T cells in the lab, which usually takes a few weeks.
- Mild chemotherapy before infusion, to make room for the new cells.
- Infusion of the CAR-T cells, followed by close monitoring.
After the infusion, the patient needs to stay near the centre for a few weeks, because side effects such as cytokine release syndrome or neurological effects can occur and must be treated quickly.
Who it is approved for
In the European Union, CAR-T therapies are approved for certain blood cancers: some types of lymphoma, B-cell acute lymphoblastic leukaemia in children and young adults, and multiple myeloma, usually after other treatments have failed or the disease has returned. Research continues in solid tumours and even some autoimmune diseases, but these are still in clinical trials.
Where it is given
CAR-T is given only at accredited centres with haematology and intensive care teams trained for these treatments. Several university hospitals in Austria, Germany, France and the United States run active CAR-T programmes.
How we can help
Together with a specialised centre, we assess whether the patient meets the criteria, obtain a cost estimate, and organise apheresis, the stay during monitoring and contact with the haematologist in Romania.
Informational article. It does not replace medical advice; treatment decisions are made with your treating doctor.